Sun Pharma's $11.75B Organon Acquisition, Explained

Sun Pharma agreed to pay $11.75B for Organon, a Merck spin-off, in the largest overseas acquisition an Indian pharma company has ever made. Only $3.68B of that is the shares; the rest is Organon's debt, which Sun takes on. To fund it, State Bank of India helped write the first outbound-takeover loan from an Indian state bank.

Sun Pharma is India's largest drugmaker, historically run with almost no debt. Organon is a $6.2B-revenue business Merck spun off in 2021, carrying about $8.6B of borrowings and a franchise in women's health and biosimilars that Sun had never built. Sun agreed to buy it for $11.75B all in cash, at $14.00 a share, roughly doubling its own revenue to $12.4B and vaulting into the top 25 pharma companies in the world. The equity cheque is only $3.68B; the other two-thirds is assumed debt, raised through an eleven-bank global syndicate. What makes it a landmark is not just the size. It is that an Indian public-sector bank helped fund an outbound takeover for the first time, under an RBI reform only months old.

The Setup, the Move, and the Point

• The setup. The merger agreement was signed on April 26, 2026, and announced the next day. Sun's US holding company acquires Organon through a merger subsidiary; Organon survives as a wholly owned subsidiary. Shareholders receive $14.00 a share in cash, with a $120M break fee and an outside date of January 26, 2027. In plain terms, enterprise value: the price of the whole business, equity plus the debt the buyer inherits. Sun pays $3.68B for the shares and takes on about $8.07B of Organon's net debt, which is why an $11.75B deal needs roughly $13B of financing arranged around it.
• The move. US antitrust cleared without a second request on June 22, the financing was fully syndicated by June 30, Organon's shareholders approved on July 23, and on August 4 CRISIL reaffirmed Sun's AAA rating after assessing the deal. What is left is the European Commission and other non-US clearances, with the close expected in early 2027.
• The point. Two lessons in one deal. For strategy: buying capability rather than volume is buying time, and Sun bought a top-three women's health franchise and a number-seven biosimilars business it could not have built inside a decade. For deal-making: in a leveraged acquisition the financing is the deal, and who will lend, on what terms, decides whether the price is even reachable.

The shape of the price: a third buys the shares, two-thirds is debt Sun takes on. That is why the financing, not the equity cheque, is the story. Sources: Organon proxy, company releases.

Deal Radar: The Numbers

Six months from rumour to shareholder approval, with the close still a European review away. Sources: Organon proxy, Sun Pharma releases.

What Actually Happened. Mumbai and Jersey City, 2026

• A low-debt buyer decided to buy capability, not volume. Sun Pharma has long been India's largest drugmaker, strong in generics but light in the higher-margin innovative and biosimilar segments the market rewards. Organon offered both at scale: a top-three women's health position and a ready biosimilars pipeline. Building either would have taken most of a decade, so Sun bought the time instead. Why that matters: this is Indian pharma's shift in one deal. The old game was competing on generic volume; the new one is buying specialty and biosimilar capability in developed markets, and paying developed-market prices to do it.
• The seller's board chose cash certainty over independence. Organon carried about 4x leverage and had run a full strategic review. An all-cash offer at a real premium to the unaffected price removed the execution risk a stock deal would have carried, especially from a foreign acquirer whose shares trade in Mumbai. The board took the certain money.
• An Indian state bank helped fund an outbound takeover for the first time. SBI's roughly $1B commitment sits inside the syndicate as the first major test of a February 2026 RBI reform letting public-sector banks finance overseas takeovers. Indian acquirers used to rely entirely on foreign lenders or capital markets for deals this size. That constraint has just loosened. In plain terms, an outbound-takeover loan: financing raised in India to buy a company abroad. Until this reform, domestic public-sector banks were effectively barred from providing it, so a deal like this had to be funded offshore.

Featured Deal: The 24% Premium That Was Really 103%

How a leak distorts the headline number. Real deal, signed April 26, 2026; shareholder-approved July 23, 2026; expected to close early 2027. Figures from SEC filings, the executed merger agreement and company releases. Not investment advice.

First, the three premiums

• Against the Friday close before the announcement, Sun paid a 24% premium. That is the number most coverage led with.
• Against Organon's mid-January close, before any rumour, the premium was about 60%. Against the April 9 ‘unaffected’ close, the one Sun and Organon's own filings use, it was 103%.
• All three are arithmetically correct. They differ only in where you start the clock, and the gap between 24% and 103% is the story.

The three-part answer

• A leak had already moved the price the headline measures from. The day before signing, the Economic Times reported a roughly $13B deal, and Organon's stock jumped about 31% in a session. So the Friday close, the basis for the 24% figure, was already inflated by the deal it was meant to measure. The premium looked small because the market had front-run it.
• The ‘unaffected’ price is the honest denominator. Filings use the April 9 close precisely because it predates the speculation, and against it the premium is 103%. That is the real transfer of value to Organon's shareholders. When a deal has leaked, the unaffected-date premium is the one that means something; the last-close premium mostly measures how much the leak priced in.
• The right premium changes how you judge the price. A 24% premium reads as Sun paying up modestly; a 103% premium reads as Sun paying roughly double the standalone value, for a leveraged asset it will spend years deleveraging. Same deal, very different picture, and the difference is entirely which base you quote.

Three premiums, all correct, and the widely-quoted one is the least meaningful. Sources: company filings, Bloomberg, CNBC.

Sector Signal: Three Things This Deal Confirms About Indian Pharma

• Indian pharma is buying developed-market capability, not just competing on price. For two decades the export story was generics volume. This deal, the largest Indian outbound pharma acquisition ever, is about owning specialty and biosimilar franchises in the US and Europe. The ambition has moved up the value chain, and so has the cheque size.
• Indian bank financing for outbound M&A has arrived. SBI helping fund this is the first real test of the February 2026 reform, and it matters beyond one deal: it means the next Indian acquirer eyeing a large foreign target has a domestic lending option that did not exist before. That widens what is fundable and, over time, who can bid.
• Buying a leveraged asset only works from a position of balance-sheet strength. Organon carried ~4x leverage alone; landing inside Sun it becomes ~2.3x, and CRISIL kept the AAA. A low-debt acquirer can absorb a high-debt target and bring the ratio down. A stretched one could not have, which is why this playbook favours the financially strongest buyers.

Nearly three times the size of Ranbaxy, the deal management cites as its integration template. Sources: Sun Pharma investor call, company filings.

Valuation Pulse: Was $11.75B Too Much for $6.2B of Revenue?

A little cash, a lot of borrowed money, and for the first time an Indian state bank inside the syndicate. Sources: Outlook Business, CRISIL, IIFL.

What ‘6x EBITDA’ means: the enterprise value equals about six years of the target's operating earnings. That is a middling multiple for pharma; the aggression in this deal is in the premium over the pre-rumour share price and in the leverage assumed, not in the earnings multiple.

The discipline. Judge this on the debt and the deleveraging, not the multiple. The multiple is ordinary, but two-thirds of the price is borrowed, and the case rests on ~$2.5B of annual free cash flow arriving on schedule to bring leverage down. CRISIL's reaffirmed AAA is the external check that the maths works, but it assumes the integration goes to plan, at nearly three times the scale of Sun's last big cross-border deal. A leveraged acquisition is only as good as the cash flow that pays the debt back.

Deal Structure Clinic: The Leveraged Cross-Border Buyout

In plain terms, a reverse triangular merger: The buyer sets up a shell subsidiary, and that shell merges into the target. The target survives and becomes a wholly owned subsidiary of the buyer, while its shareholders are paid out in cash. It is the standard way to acquire a US public company while keeping its contracts and licences intact.

In plain terms, assumed debt: The target's own borrowings do not disappear at closing; the buyer inherits them. Here that is about $8 billion, which is why the deal costs $11.75B in enterprise terms but only $3.68B in equity, and why arranging the borrowing was the hard part.

Three mechanics this deal showcases

• The equity price is the small number; the financing is the large one. Sun writes a $3.68B equity cheque but has to arrange roughly $13B, because it is refinancing Organon's debt as well as paying shareholders. In a leveraged buyout the question is never only what you pay; it is who will lend the rest, and on what terms. Read the financing before the price.
• A syndicate spreads the risk that no single lender will carry. Three banks underwrote, then eight more joined to raise over $10B, because a loan this size is too large and too concentrated for one balance sheet. That SBI could take a place in that syndicate is the regulatory change that makes this deal a landmark, not just a large transaction.
• The rating is the deal's external scorecard. Sun entered with an AAA and a near-net-cash balance sheet, and CRISIL reaffirmed it after modelling the acquisition. That reaffirmation is what tells the market the leverage is carriable; without it, the same debt on the same assets would read very differently.

A leveraged target lands on a low-debt buyer, and the combined ratio falls to something a rating agency will bless. Sources: CRISIL, company disclosures.

M&A 101: Financing a Large Foreign Acquisition

In plain terms, a leveraged acquisition: Buying a company mostly with borrowed money rather than cash or shares. The buyer puts in some equity and funds the rest with debt, often secured against the target's own cash flow, so the deal only works if that cash flow can service the loan.

The three steps, using this deal

• Step 1: Separate the equity price from the enterprise price. What you pay shareholders and what the deal actually costs are two different numbers, and the gap is the target's debt. Sun's shareholders' cheque was $3.68B, but the enterprise value was $11.75B, because about $8B of Organon's borrowings came with it. Size the financing to the enterprise value, not the equity.
• Step 2: Line up the lenders before you fix the price. Financing was reportedly arranged in the $10–14B range even at the non-binding stage, well before terms were final. You do not agree a leveraged deal and then look for the money; you confirm it is there first, because a price you cannot fund is not a price. Sun syndicated eleven banks to be certain.
• Step 3: Make sure the combined balance sheet can carry it, and get that verified. A leveraged target only works on a buyer strong enough to absorb it: Organon's ~4x becomes ~2.3x inside Sun, and CRISIL reaffirmed the AAA. The external rating is not a formality; it is the independent confirmation that the plan to pay the debt down is credible. Secure it before you celebrate.

Approved, cleared in the US and fully funded; the European review and the close are what remain. Sources: Organon proxy, Sun Pharma filings.

Where This Fits in Buy-Side and Cross-Border M&A Advisory

Kautilya covers deal-structure teardowns like this one because the mechanics — assumed debt, syndicated financing, and the gap between a headline premium and the one that actually matters — repeat across markets far smaller than a $11.75B pharma buyout. If you are evaluating how buy-side deal origination and structuring work for mid-market acquisitions in India, see what buy-side M&A advisory is and, for the search-fund-specific version of financed acquisitions, what a search fund is.